openPR Logo
Press release

Orphan Drugs Market Projection By Top Key Players – Amgen Inc., Bayer AG, F. Hoffmann-La Roche Ltd, Alexion Pharmaceuticals Inc., Novo Nordisk A/S, Novartis AG Market Research Forecast 2028

10-21-2021 01:30 PM CET | Health & Medicine

Press release from: Fortune Business Insights™

Orphan Drugs Market Forecast 2021-2028

Orphan Drugs Market Forecast 2021-2028

A new market study, titled “Orphan Drugs Market Forecast 2021-2028” has been featured on Fortune Business Insights™.



***Get Latest Updated Market Research Report with Free Sample Report

Market Overview:

The global orphan drugs market size is projected to reach USD 340.84 billion by the end of 2027. Increasing number of regulatory approvals will have a positive impact on the growth of the overall market in the coming years. According to a report published by Fortune Business Insights, titled “Orphan Drugs Market Size, Share & COVID-19 Impact Analysis, By Therapy Area (Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy, and Others), By Drug Type (Biologics, and Non-Biologics), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Sales, and Others), and Regional Forecast, 2020-2027,” the market was worth USD 151.00 billion in 2019 and will exhibit a CAGR of 10.5% during the forecast period, 2020-2027.

Orphan drugs are medicinal products that are intended at the treatment of severe and life—threatening conditions including cancer. They are normally associated with the treatment of very rare diseases (affecting 1 in every 2000 people). The difficulty associated with the treatment of critical diseases has yielded massive investments in research and development. The presence of numerous large scale orphan drug manufacturers across the world will emerge in favor of growth of the overall market in the coming years. The increasing number of regulatory approvals associated with orphan drugs, coupled with increasing clinical trials related to these drugs will create several growth opportunities for the market in the coming years.

Request for Free Sample Report PDF @ https://www.fortunebusinessinsights.com/enquiry/sample/orphan-drugs-market-100088

Orphan drugs are used for the treatment of severe and life-threatening diseases. The high emphasis on research and development of these drugs are consequential to the difficulty associated with the treatment of the disease. Due to increasing incidence of such life-threatening diseases, including cancer, there are several companies that are operating across the globe. The high prevalence of infectious diseases in developed as well as developing countries will bode well for the growth of the market in the coming years. The presence of several large scale manufacturers will contribute to the growth of the market. The increasing demand for immunomodulators in emerging as well as developed countries will have a positive impact on the growth of the overall market in the foreseeable future.

Non-essential Medical Treatments to be Postponed during the Covid-19 Pandemic, Leaving Manufacturers in a State of Turmoil

The recent coronavirus outbreak has instilled panic among people across the world. Accounting to the rapid spread of the disease in several countries, strict measures have been taken to curb the epidemic. Moreover, governments across the world are implementing strategies that will result in more attention towards the treatment of the coronavirus disease. This has indirectly halted the non-essential and even a few long-term disease treatment procedures. This has certainly left manufacturers in a state of confusion. Given the current situation, the market is set to be negatively affected by the coronavirus outbreak.

Increasing Number of Regulatory Approvals will Emerge in Favor of Orphan Drugs Market Growth

The report encompasses several factors that have contributed to the growth of the overall market in recent years. Accounting to the massive potential held by orphan drugs, there are numerous clinical trials associated with the drugs. The increasing number of successful clinical trials has resulted in an increase in the number of regulatory approvals across the world. In May 2019, Pfizer announced that it has received approval from the US Food and Drug Administration for its latest products aimed at treatment of cardiomyopathy. The company announced that it has received approval from the FDA for VYNDAQEL and VYNDAMAX, two products that have shown signs of promise in the clinical phases. Fortune Business Insights states that increasing number of such regulatory approvals for products of large scale companies will have a positive impact on the growth of the overall market in the coming years.

List of companies profiled in the report:

Amgen Inc. (Thousand Oaks, U.S.)
Bayer AG (Leverkusen, Germany)
F. Hoffmann-La Roche Ltd (Basel, Switzerland)
Alexion Pharmaceuticals Inc. (Boston, U.S.)
Novo Nordisk A/S (Bagsværd, Denmark)
Novartis AG (Basel, Switzerland)
Bristol-Myers Squibb Company (New York, U.S.)
AstraZeneca (Cambridge, U.K.)
DAIICHI SANKYO COMPANY, LIMITED (Tokyo, Japan)
GlaxoSmithKline plc (Brentford, U.K.)
Other Players

Ask for Customization @ https://www.fortunebusinessinsights.com/enquiry/customization/orphan-drugs-market-100088

North America Currently Dominates the Market; Increasing Spending on R&D by Major Companies to Aid Growth

The report analyses the ongoing market trends across five major regions, including North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. Among all regions, the market in North America currently dominates the market. The high spending on research and development of orphan drugs, coupled with the presence of several large-scale local manufacturers will bode well for market growth. The rising demand for the product in the United States as well as Canada will also contribute to the growth of the market in the coming years. As of 2019, the market in North America was worth USD 81.22 billion and this value is projected to increase further in the coming years. The market in Europe will derive growth from the adoption of technologically advanced manufacturing equipment by major companies in the region.

Industry Developments:

August 2018: Ultragenyx announced that it has received FDA approval for Mepsevii (vestronidase alfa) in Europe. The product is aimed at the treatment of Mucopolysaccharidosis VII.

Speak To Analyst @ https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/orphan-drugs-market-100088

NOTE : Our team is studying Covid19 and its impact on various industry verticals and wherever required we will be considering covid19 footprints for a better analysis of markets and industries. Cordially get in touch for more details.

"INDRAYANI NIWAS", HANUMAN NAGAR, SHRIGONDA.

Fortune Business Insights™ delivers accurate data and innovative corporate analysis, helping organizations of all sizes make appropriate decisions. We tailor novel solutions for our clients, assisting them to address various challenges distinct to their businesses. Our aim is to empower them with holistic market intelligence, providing a granular overview of the market they are operating in.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Orphan Drugs Market Projection By Top Key Players – Amgen Inc., Bayer AG, F. Hoffmann-La Roche Ltd, Alexion Pharmaceuticals Inc., Novo Nordisk A/S, Novartis AG Market Research Forecast 2028 here

News-ID: 2436779 • Views: 348

More Releases from Fortune Business Insights™

Small Satellite Market Share, Growth by Geographical Region, Application, Driver …
The global small satellite market size is expected to experience significant growth by reaching USD 10.75 billion by 2028 while exhibiting a CAGR of 12.55% in 2021 and 2028. Fortune Business Insights, in its report titled “Small Satellite Market, 2021-2028.”, observes that the market stood at USD 4.08 billion in 2020. Factors such as the increasing adoption of modern technologies such as the internet of things (IoT) in the manufacturing
Unmanned Underwater Vehicles (UUV) Market 2021 with Top Countries Data Analysis …
The global unmanned underwater vehicles market size is expected to reach USD 9,502.7 million by 2028, exhibiting a CAGR of 17.59% during the forecast period. The increasing application of UUVs in underwater search and survey, communication, navigation, and maritime surveillance will propel the healthy growth of the market, states Fortune Business Insights, in a report, titled “Unmanned Underwater Vehicles (UUV) Market, 2021-2028.” The market size stood at USD 2,960.8 million
How Power Magnetics for MV AC Drive Market 2021 is Booming Worldwide with Top Le …
The global power magnetics for MV AC drive market size expected to showcase exponential growth by reaching USD 1.48 billion by 2027 while exhibiting a CAGR of 5.4% between 2020 and 2027. The growth is attributable to the favorable government policies supporting green energy applications and the rapid-paced urbanization that is anticipated to surge the adoption of advanced power magnetics for MV AC drive products globally. Fortune Business Insights in
How Industrial Wood Pellet Market 2021 is Booming Worldwide with Top Leading Pla …
The global industrial wood pellet market analysis, size is set to flourish stoked by the increased demand for clean energy, observes Fortune Business Insights™ in a report, titled, “Industrial Wood Pellet Market Size, Share & COVID-19 Impact Analysis, By Feedstock (Forest Wastes, Agricultural Waste, and Others), By Application (Power Generation, and Combined Heat and Power [CHP]), and Regional Forecast, 2020-2027.” The market size was USD 5.54 billion in 2019 and

All 5 Releases


More Releases for Orphan

FDA grants orphan drug status to Vicore
US Food and Drug Administration has awarded Vicore Pharmaceuticals with orphan Drug designation for the treatment of Idiopathic Pulmonary Fibrosis (IPF). FDA’s Orphan Drug Designation program provides certain incentives for companies developing therapeutics to treat rare diseases or conditions, defined as those affecting less than 200,000 individuals in the U.S. A drug candidate and its sponsor must meet several key criteria in order to qualify for, and obtain, orphan drug
Orphan Drugs for Cancer Pipeline Analysis
A huge market opportunity is offered by small patient population which suffers from rare or orphan diseases. Among the category of new orphan drugs, Oncology account for the largest disease group in recent years. It has been observed that majority of the orphan drugs in the clinical stages are for rare cancer disease drugs, and are in the late stages of the pipeline. Some of the drugs are being developed
US Orphan Drug Pipeline Analysis
In recent years, the pharmaceutical industry has been experiencing a paradigm shift. While a large pool of patients was considered as a major source of revenue for pharma companies in the past, the focus is now gradually shifting to small sections of patients suffering from rare disease. In US, this pool of patients is gradually growing and orphan drugs are becoming an extremely attractive business proposition for the pharmaceuticals industry.
Europe Orphan Drugs Pipeline Analysis
“Europe Orphan Drugs Pipeline Analysis” by PNS Pharma gives comprehensive insight on the various drug profiles under Orphan Drugs status in Europe. Research report covers all the ongoing drug development in various phases. Each drug profiles include detailed information like: Originator, Owner, Collaborator, Technology Provider, Licensee, Development Phase, Development Indications, Mechanism of Action, Chemical Formula, Country of Development and detailed analysis on the development process. The information for particular drug
Global Orphan Drug Pipeline Analysis
In recent years, the pharmaceutical industry has been experiencing a paradigm shift. While a large pool of patients was considered as a major source of revenue for pharma companies in the past, the focus is now gradually shifting to small sections of patients suffering from rare disease. In US & Europe, this pool of patients is gradually growing and orphan drugs are becoming an extremely attractive business proposition for the
Global Orphan Drug Clinical Pipeline Insight 2022
“Global Orphan Drug Clinical Pipeline Insight 2022” report gives comprehensive insight on various clinical and non-clinical aspects associated with ongoing clinical trials of 808 orphan designated drugs across the globe. The in-depth clinical insight presented in the report helps the reader to analyze and identify the various stakeholders involved in the clinical development and commercialization of orphan designated drugs in the global market. Currently there are more than 300 orphan